Thomson, Rogers is Investigating Cases of Alleged Adverse Outcome from the SculpSure Treatment

Posted March 26, 2018

Share This

Share on Facebook Share on Twitter Share on Linkedin Share on Google+ Share By Email

SculpSure is a device manufactured by Cynosure Inc. that treats non-invasive lipolysis of the abdomen and flanks.  In 2015, its use was approved by the FDA in the United States.  In 2016, its use was approved by Health Canada.  SculpSure treatments are often performed at medical spas.

Questions and concerns have emerged about SculpSure’s promises as a painless and effective fat-reducing procedure.

In 2017, a class action lawsuit was issued against Cynosure Inc. by a number of physicians in the U.S. who have alleged that they (or their spas) purchased the devices under false information about its effectiveness.  It has been alleged in that lawsuit that the device is effectively useless for the purpose for which it was intended, that it causes excessive pain to patients, that multiple rounds of treatment are required, and that results are unsatisfactory.  For more information on the U.S. class action, see Vita 4 Life, Inc. v. Cynosure, Inc.

Thomson, Rogers has recently been retained to investigate the possibility of initiating claims, including a potential class action claim in Canada against Cynosure Inc. (the manufacturer of SculpSure), Freedom Medi-Spa, and/or other physicians or medical spas that have treated their patients with SculpSure.

If you or someone you know has undergone the SculpSure treatment in Canada, has suffered an alleged adverse outcome (including, but not limited to, excessive pain, nodules, damaged fat tissue, or scarring), and has concerns about the quality of the information provided about the procedure before consent was given to proceed, please contact us for a free and confidential consultation by emailing Deanna S. Gilbert (dgilbert@thomsonrogers.com) or calling 416-868-3205.